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To determine why incidence of mucormycosis infec-
tions was increasing in a large university hospital in Bel-
gium, we examined case data from 2000–2009. We found 
the increase was not related to voriconazole use but most 
probably to an increase in high-risk patients, particularly 
those with underlying hematologic malignancies. 
I
n September 2009, Bitar et al. reported an increasing in-
cidence of mucormycosis in France from 1997 through 
2006 (1). Their epidemiologic study was based on Interna-
tional Classiﬁ  cation of Diseases, 10th Revision (ICD-10), 
codes extracted from hospital information systems from an 
estimated 95% of public and private hospitals in France. 
This study is particularly interesting because population-
based estimates of the incidence of mucormycosis are 
scarce (2). However, as the authors state, ICD code–based 
evaluations have limitations; such limitations are mainly 
related to difﬁ  culties encountered with the diagnosis of 
mucormycosis in clinical practice. Conventional diagnos-
tic tools lack sensitivity. Moreover, distinction between 
colonization and infection is problematic in the absence of 
invasive procedures or autopsy data. Thus, epidemiologic 
studies on mucormycosis are often hampered by the limited 
number of documented cases. 
Several surveys have been conducted in large US 
transplant centers. Based on these studies, the increasing 
incidence of mucormycosis has been linked to the wide-
spread use of voriconazole prophylaxis in high-risk patients 
(3,4). In contrast with the study in France, these surveys 
have the limitation of focusing on particular risk groups, 
mainly cancer patients, and do not provide a general esti-
mate on the incidence of mucormycosis. In our study, we 
determined the incidence rate of invasive mucormycosis in 
a large university hospital in Belgium over a 10-year period 
and reviewed the clinical data of the patients with proven 
or probable disease.
The Study
Case ﬁ  nding was based on culture and pathology data 
and not on ICD codes. Culture data from all patients hospi-
talized at the University Hospitals of Leuven (Belgium) from 
2000 through 2009 were retrieved from the Sirscan 2000 
system (i2a, Montpelier, France). Computer queries were 
run to retrieve all reports from histologic examinations of tis-
sue specimens to which the Leiden code “fungus” had been 
assigned (5). Medical records of all patients with culture or 
histopathologic evidence for Mucorales spp. organisms were 
reviewed, and all patients were classiﬁ  ed as having proven 
or probable invasive mucormycosis according to European 
Organization for Research and Treatment of Cancer and 
Mycoses Study Group (EORTC-MSG) criteria (6).
Over this 10-year time period, 31 patients with mu-
cormycosis were identiﬁ  ed: 21 with proven and 10 with 
probable disease. The annual incidence increased from 0.019 
cases/10,000 patient-days in 2000 to 0.148 cases/10,000 pa-
tient-days in 2009 (Spearman correlation coefﬁ  cient 0.75; 
p = 0.01) (Figure 1). The incidence increased mainly from 
2005–2009. Averaged over the 10 years, the incidence was 
0.058/10,000 patient-days. The sex ratio (M/F) was 16/15; 
mean age was 54 years (median 59 years, range 12–79 
years). Nineteen (61%) of 31 mucormycosis patients had 
a hematologic disorder; 8 patients underwent a hematopoi-
etic stem cell transplantation. Other underlying conditions 
were diabetes mellitus (n = 2), solid organ transplantation 
(n = 4), surgery/trauma (n = 4), autoimmune disorder (n = 
1), and HIV infection (n = 1).
The number of patients belonging to the risk groups dia-
betes mellitus, solid organ transplantation, hematologic dis-
order/malignancy, and hematopoietic stem cell transplanta-
tion was determined based on International Classiﬁ  cation of 
Diseases, 9th Revision, Clinical Modiﬁ  cation (ICD-9-CM), 
codes entered in the hospital information system (available 
up to the end of 2008). An increase in the number of diabe-
tes mellitus (p<0.01) and hematologic disorder/malignancy 
(p<0.01) patients (Spearman correlation; Table) was seen 
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Figure 1. Incidence of mucormycosis cases in a hospital in Belgium, 
2000–2009. HSCT, hematopoietic stem cell transplantation.Increasing Incidence of Mucormycosis, Belgium
from 2000 through 2008. The speciﬁ  c annual incidence 
rate (deﬁ  ned as the number of mucormycosis cases per risk 
group over the number of risk patients per year) for these 4 
risk groups did not increase signiﬁ  cantly during this period 
(Spearman correlation; p>0.01) (Table; Figure 2).
None of the 31 patients had received voriconazole 
prophylaxis (per institutional policy). Mucormycosis de-
veloped in 1 patient while that patient was receiving vori-
conazole therapy for invasive aspergillosis.
Clinical signs included pulmonary (51.5%), dissemi-
nated (23%), cutaneous (13%), sinus (6.5%), cerebral 
(3%), and mycetoma (3%) mucormycosis. A high per-
centage (45%) of co-infections with Aspergillus spp. was 
recorded. Five of the 6 patients showing a halo sign on 
chest computed tomography scan were co-infected with 
Aspergillus spp.
The death rate was 65%. For 48% of the patients, death 
was directly related to mucormycosis infection.
Conclusions
We report an increasing incidence rate of invasive mu-
cormycosis not related to the use of voriconazole, either 
prophylactically or therapeutically, in a university hospital 
in Belgium. Pongas et al. calculated that 49% of mucormy-
cosis cases were encountered in the setting of voriconazole 
prophylaxis (3). A case–control observational study identi-
ﬁ  ed voriconazole prophylaxis as an independent risk factor 
for the development of mucormycosis (7). However, in our 
series, none of the 31 patients had received voriconazole 
prophylaxis, and mucormycosis developed in only 1 pa-
tient who was receiving voriconazole therapy for invasive 
aspergillosis.
Compared with the study from France (6.8%), our 
study reported a notably high percentage (23%) of cases of 
disseminated disease (1). However, high incidences, up to 
17% of cases, were also reported from other recent clinical 
registries (8,9). In our hospital, the number of patients with 
disseminated mucormycosis infection may be increasing; 1 
case was diagnosed in 2000, 1 in 2005, 2 in 2008, and 3 in 
2009. This ﬁ  nding possibly reﬂ  ects the growing population 
of severely immunosuppressed patients.
The death rate of 65% is consistent with death rates 
reported in recent clinical registries (≈50%) but appears to 
be much higher than rates reported in the study in France. 
However, this discrepancy might be merely a reﬂ  ection 
of differences in case deﬁ  nitions (1,8,9). We expect death 
rates to be higher in studies or surveillances that apply more 
stringent case deﬁ  nitions; cases with only fungal coloniza-
tion, not invasive disease, are less likely to be included in 
these studies.
During the 10-year period, the most important risk 
group, namely patients with a hematologic disorder/malig-
nancy, expanded considerably. The population of patients 
with diabetes also increased, but mucormycosis in this host 
population is quite rare in our institution (only 2 cases in 10 
years). A decreasing number of published mucormycosis 
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Table. Specific annual incidence rate of mucormycosis cases per risk group in a hospital in Belgium, 2000–2008* 
Year Diabetes mellitus 
Solid organ 
transplantation 
Hematologic disorder/ 
malignancy HSCT 
2000 0/3,087  0/235  1/684  0/96
2001 0/3,328  0/217  2/557  1/86
2002 0/3,319  0/207  0/650  0/87
2003 0/3,662  0/245  0/775  0/118 
2004 1/3,845  0/217  0/787  0/126 
2005 1/4,121  1/191  1/853  0/103 
2006 0/4,235  2/251  5/1,061  3/91
2007 0/4,328  0/279  0/942  0/121 
2008 0/4,477  1/267  3/859  1/116 
p value for the increase in 
  No. patients per risk group  <0.01 0.12 <0.01 0.19
  Specific annual incidence rate  0.81 0.11 0.91 0.55
*Values are no. cases per risk group/no. patients admitted per year with that risk factor, unless otherwise indicated. Data for risk group patients are based 
on codes from the International Classification of Diseases, 9th Revision, Clinical Modification, available 2000–2008. HSCT, hematopoietic stem cell 
transplantation.  
Figure 2. Speciﬁ  c annual incidence rate for the risk groups solid 
organ transplantation, hematologic disorder/malignancy, and 
hematopoietic stem cell transplantation (HSCT) in a hospital in 
Belgium, 2000–2008.
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2000 2001 2002 2003 2004 2005 2006 2007 2008cases since the 1990s in patients with diabetes mellitus as 
underlying illness was reported in a large review of the lit-
erature (10). This ﬁ  nding could be a consequence of better 
glycemic control and decreasing rates of diabetic ketoaci-
dosis and of the widespread use of statins in patients with 
diabetes (11).
Several limitations of our study can be mentioned. 
First, 5 cases of mucormycosis were diagnosed on the basis 
of histopathologic ﬁ  ndings only. Second, the numbers of 
the risk populations were derived from ICD-9-CM codes 
and are thus subject to all inaccuracies associated with dis-
charge coding of patients. Third, we used the EORTC-MSG 
criteria for classiﬁ  cation of cases, but, unlike other ﬁ  lamen-
tous fungal pathogens that target immunocompromised 
hosts, Mucorales spp. organisms infect a broader and more 
heterogeneous population. Thus, invasive mucormycosis 
also occurs in immunocompetent patients without any host 
factor as deﬁ  ned by these criteria. As such, invasive proce-
dures are necessary in immunocompetent patients to enable 
the diagnosis of proven invasive mucormycosis according 
to the EORTC-MSG criteria. However, we estimate the ef-
fect of this limitation to be minor because in immunocom-
petent patients, biopsy procedures are generally feasible, 
particularly because mucormycosis is most often seen as 
a cutaneous infection in these patients. Finally, our results 
are single-institution data and are not necessarily represen-
tative of other institutions or other geographic regions.
In conclusion, the increasing incidence of mucormy-
cosis shown in our study was not related to the prior use 
of voriconazole. Rather, the increasing incidence was most 
probably associated with an increasing number of patients 
who had an underlying hematologic malignancy.
Acknowledgments
We sincerely thank Hilde Pince for providing the numbers of 
the different populations at risk. We are also grateful to Thomas 
De Rijdt for providing antifungal treatment data.
Ms Saegeman is a microbiologist in training at Catholic Uni-
versity of Leuven, Belgium. Her clinical and research interests 
focus on fungal infections.
References
  1.   Bitar D, Van Cauteren D, Lanternier F, Dannaoul E, Che D, Dromer 
F, et al. Increasing incidence of zygomycosis (mucormycosis), 
France, 1997–2006. Emerg Infect Dis. 2009;15:1395–401. DOI: 
10.3201/eid1509.090334
  2.   Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The 
epidemiological features of invasive mycotic infections in the San 
Francisco Bay area, 1992–1993: results of population-based labo-
ratory active surveillance. Clin Infect Dis. 1998;27:1138–47. DOI: 
10.1086/514975
  3.   Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-
associated zygomycosis: a signiﬁ   cant consequence of evolving 
antifungal prophylaxis and immunosuppression practices. Clin Mi-
crobiol Infect. 2009;15(Suppl 5):93–7. DOI: 10.1111/j.1469-0691
.2009.02988.x
    4.    Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis 
after voriconazole treatment in recipients of hematopoietic stem-
cell transplants. N Engl J Med. 2004;350:950–2. DOI: 10.1056/
NEJM200402263500923
  5.   Faverly D, Renard F, Drijkoningen M, Scheiden R. Breast cancer 
screening pathology: an assessment of the practise and needs in 
Belgium and Luxembourg. Virchows Arch. 2000;437:354–9. DOI: 
10.1007/s004280000254
  6.   De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calan-
dra T, et al. Revised deﬁ  nitions of invasive fungal disease from the 
European Organization for Research and Treatment of Cancer/Inva-
sive Fungal Infections Cooperative Group and the National Institute 
of Allergy and Infectious Diseases Mycoses Study Group (EORTC/
MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21. DOI: 
10.1086/588660
  7.   Kontoyiannis DP, Lionakis M, Lewis R, Chamilos G, Healy M, 
Perego C, et al. Zygomycosis in a tertiary-care cancer center in the 
era of Aspergillus-active antifungal therapy: a case-control obser-
vational study of 27 recent cases. J Infect Dis. 2005;191:1350–60. 
DOI: 10.1086/428780
  8.   Petrikkos G. A global registry for zygomycosis: results from the ﬁ  rst 
ECMM study and plans for the future. In: Abstracts of the 17th Con-
gress of the International Society for Human and Animal Mycology; 
Tokyo; 2009 May 25–29. Abstract MO-10–5.
  9.   Rüping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flör C, Beisel C, 
et al. Forty-one recent cases of invasive zygomycosis from a global 
clinical registry. J Antimicrob Chemother. 2010;65:296–302. DOI: 
10.1093/jac/dkp430
10.    Roden MM, Zaoutis T, Buchanan W, Knudsen T, Sarkisova T, 
Schaufele R, et al. Epidemiology and outcome of zygomycosis: a 
review of 929 reported cases. Clin Infect Dis. 2005;41:634–53. DOI: 
10.1086/432579
11.   Kontoyiannis DP. Decrease in the number of reported cases of zy-
gomycosis among patients with diabetes mellitus: a hypothesis. Clin 
Infect Dis. 2007;44:1089–90. DOI: 10.1086/512817
Address for correspondence: Katrien Lagrou, University Hospitals 
Leuven, Dienst Laboratoriumgeneeskunde, Herestraat 49, 3000 Leuven, 
Belgium; email: katrien.lagrou@uz.kuleuven.ac.be
DISPATCHES
1458  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 9, September 2010
The opinions expressed by authors contributing to this journal do 
not necessarily reﬂ  ect the opinions of the Centers for Disease Con-
trol and Prevention or the institutions with which the authors are 
afﬁ  liated.
Search past issues of EID at www.cdc.gov/eid